These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1308 related articles for article (PubMed ID: 33773286)
1. Effective degradation of EGFR Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286 [TBL] [Abstract][Full Text] [Related]
2. Discovery of highly potent and selective CRBN-recruiting EGFR Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176 [TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of selective degraders of EGFR Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162 [TBL] [Abstract][Full Text] [Related]
4. Discovery of potent small molecule PROTACs targeting mutant EGFR. Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686. Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation. Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656 [TBL] [Abstract][Full Text] [Related]
7. Discovery of highly potent and selective EGFR Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818 [TBL] [Abstract][Full Text] [Related]
8. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075 [TBL] [Abstract][Full Text] [Related]
9. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937 [TBL] [Abstract][Full Text] [Related]
10. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC). Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins. Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458 [TBL] [Abstract][Full Text] [Related]
13. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291 [TBL] [Abstract][Full Text] [Related]
14. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR Xu J; Zhu GY; Cao D; Pan H; Li YW Biomed Pharmacother; 2019 Jul; 115():108860. PubMed ID: 31055235 [TBL] [Abstract][Full Text] [Related]
15. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830 [TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands. Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067 [TBL] [Abstract][Full Text] [Related]
18. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC). Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869 [TBL] [Abstract][Full Text] [Related]
19. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors. Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR). Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]